0001104659-23-028617.txt : 20230303 0001104659-23-028617.hdr.sgml : 20230303 20230303201054 ACCESSION NUMBER: 0001104659-23-028617 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230302 FILED AS OF DATE: 20230303 DATE AS OF CHANGE: 20230303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Derby Michael CENTRAL INDEX KEY: 0001809613 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41475 FILM NUMBER: 23707120 MAIL ADDRESS: STREET 1: 303 SOUTH BROADWAY STREET 2: SUITE 125 CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PaxMedica, Inc. CENTRAL INDEX KEY: 0001811623 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 303 SOUTH BROADWAY, SUITE 125 CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 914-987-2876 MAIL ADDRESS: STREET 1: 303 SOUTH BROADWAY, SUITE 125 CITY: TARRYTOWN STATE: NY ZIP: 10591 4 1 tm238562d1_4.xml OWNERSHIP DOCUMENT X0306 4 2023-03-02 0 0001811623 PaxMedica, Inc. PXMD 0001809613 Derby Michael C/O PAXMEDICA, INC. 303 SOUTH BROADWAY, SUITE 125 TARRYTOWN NY 10591 1 1 1 0 Executive Chairman Common Stock 2023-03-02 4 S 0 10497 1.94 D 374503 D Common Stock 2023-03-03 4 S 0 18968 1.90 D 355535 D Common Stock 7336745 I TardiMed Sciences, LLC The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person. This sale price represents the weighted average sale price of the shares sold ranging from $2.09 to $1.87 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. This sale price represents the weighted average sale price of the shares sold ranging from $1.98 to $1.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. /s/ Stephen D. Sheldon, Jr. Attorney-in-Fact 2023-03-03